Press releases

System had earlier received FDA clearance and CE Mark approval for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures.

Bipartisan bill is intended to modernize the U.S. patent system

Low-profile, high-pressure balloon offers physicians exceptional performance in a single platform for peripheral angioplasty procedures

Company will participate in the healthcare conference on June 22 in Boston. Learn how to watch the webcast or replay.

Patents relate to coatings (drug and polymer) for drug-eluting stents

Action affects products distributed in U.S. and its territories; Atlantis® SR Pro available immediately as a substitute

Boston Scientific becomes the first and only company to offer two distinct drug-eluting stents to treat small vessels

New technology designed to improve lead anchoring for physicians to be introduced at INS World Congress

12-month clinical data demonstrate low adverse event rates for Boston Scientific's 2.25 mm PROMUS Element Platinum Chromium Stent

Results for Boston Scientific WATCHMAN device presented at EuroPCR

Five-year data from RISA Trial presented at ATS adds to clinical evidence showing long-term safety of Boston Scientific's Alair® Bronchial Thermoplasty System

Jury in the District of Delaware found that Cordis owed Boston Scientific approximately $19.5 million for infringing its Jang patent.

Patients receive first device-based treatment for severe asthma

Elliott to remain on Board as non-executive director.

Company sponsors additional efforts to promote education and awareness of severe asthma

Innovative Fine Needle Aspiration technology expands diagnostic capabilities in pancreas and gastrointestinal tract

World's smallest and thinnest high-energy CRT-Ds and ICDs offer new features to optimize patient management

ALTITUDE analyzes outcomes data from patients monitored by the LATITUDE® Patient Management system.

Implanting U.S. centers can qualify for a full refund if they have to replace a COGNIS® CRT-D device due to unmanageable PNS within six months post-implant.

System used in 25,000 patient procedures at 600 facilities worldwide since 2007

Radiofrequency ablation catheter designed to treat a variety of arrhythmias

The scheduled clinical presentations will provide new insights for physicians who treat patients with heart disorders including sudden cardiac arrest, atrial fibrillation and heart failure.

Company will participate in the healthcare conference on May 11 in Las Vegas. Learn how to watch the webcast or replay.

Company will participate in the healthcare conference on May 2 in Boston. Learn how to watch the webcast or replay.

Innovative alloy designed to improve new coronary stent's acute performance

“We had several notable accomplishments during the quarter that illustrate progress toward strategic milestones,” said Ray Elliott, Company President and CEO.

Company will webcast its conference call with financial results and business highlights for Q1 2011 on April 21. Learn how to tune in.

Study will evaluate safety and effectiveness in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

Reduction of geographic miss and bail-out stenting observed with highly visible PROMUS Element Stent

Lower event rates for new alloy and stent design versus older drug-eluting stent model

Clinical presentations to include 12-month data on PROMUS Element™ Platinum Chromium Stent

New technology designed to improve lead anchoring speed and consistency for physicians

Company will provide an update on its Cardiology, Rhythm and Vascular (CRV) Group initiatives involving coronary stent and structural heart technologies

Company will participate in the healthcare conference on March 15. Learn how to watch the webcast or the replay.

Third-generation bare-metal stent offers improved acute performance in treating patients with coronary artery disease

Company adds innovative technology for atrial fibrillation patients with high stroke risk

Company's third-generation drug-eluting stents now available in rapidly growing market

Company will participate in the healthcare conference on March 2. Learn how to tune in.

New products expand treatment options for healthcare providers

Scholarship Fund Honors Company's Late Chief Medical and Scientific Officer

Journal of American College of Cardiology sub-analysis showed women received a greater clinical benefit from cardiac resynchronization therapy defibrillators (CRT-Ds) than men

New system integrates market-leading Renegade HI-FLO Microcatheter with high-torque Fathom-16 Steerable Guidewire for peripheral embolization procedures

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net...

Complaint involves Guidant's conduct leading to its recalls of ICDs in 2005, before Boston Scientific’s 2006 acquisition of Guidant

Procedure performed as part of BLOCk-CTI clinical trial evaluating treatment of Type 1 atrial flutter

PLATINUM China trial to support Chinese regulatory approval of next-generation platinum chromium stent

Fourth-generation stent features bioabsorbable polymer and everolimus drug coating

Distribution agreement will allow Company to expand the service it offers customers in Japan

A live webcast and archived replay of this call will be available

Innovative left atrial appendage closure device offers alternative for patients with atrial fibrillation and strengthens Company's position in emerging structural heart markets